News

Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu for the prevention and treatment of influenza or flu in the US. Under the terms of the…
Read More...

Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for the treatment of adult…
Read More...

Merck, known as MSD outside the United States and Canada, and Eisai announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for KEYTRUDA,…
Read More...

As part of the Company’s 10-year initiative to drive progress against tuberculosis (TB), Johnson & Johnson today announced that it has launched an international research consortium…
Read More...

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic…
Read More...

Avalon GloboCare Corp. announced that they have established a strategic partnership with GE Healthcare. The partnership will accelerate Avalon’s standardization, automation and…
Read More...

Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, is pleased to report that the Company has executed a license agreement with Alfasigma S.p.A to develop and…
Read More...

Baxter International Inc. announced the U.S. Food and Drug Administration (FDA) approval of Myxredlin (Insulin Human in 0.9% Sodium Chloride Injection). Myxredlin (pronounced…
Read More...

Sandoz, a Novartis division and a global leader in biosimilars, announced the first patient enrolled in ROSALIA, an integrated Phase I/III clinical study for its proposed biosimilar…
Read More...

ACADIA Pharmaceuticals Inc. announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with…
Read More...

Vertex Pharmaceuticals Incorporated announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the VX-445 (elexacaftor), tezacaftor and…
Read More...

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral…
Read More...

Celltrion and Nan Fung Group announced the establishment of Vcell Healthcare Limited, a Joint Venture company between both parties. At the formation of the Joint Venture, Vcell…
Read More...

Aridis Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to AR-501, the Company's inhaled formulation of gallium citrate for…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of an extension application to the European Medicines Agency (EMA) for subcutaneous (under the…
Read More...

MilliporeSigma and the Broad Institute of MIT and Harvard announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for…
Read More...

Mallinckrodt plc and Silence Therapeutics plc announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the…
Read More...

"It is exciting news for MS patients in China that Gilenya has received fast approval. The approval of Gilenya and the upcoming regulatory review for Mayzent demonstrate our commitment…
Read More...

Results from the INMARK study, a randomised, double-blind clinical trial of Ofev (nintedanib) vs. placebo (12 weeks) followed by an open label period (40 weeks) in patients with…
Read More...

Astellas Pharma Inc. and Frequency Therapeutics, Inc. announced that they have entered into an exclusive license agreement to develop and commercialize Frequency’s regenerative…
Read More...